Clinical Trials on ADHD in Australia

Total 7 results

Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

Adult Attention-deficit Hyperactivity Disorder (ADHD)

Australia
Shire

Completed

Drug Use Study With Intuniv® in Australia

Attention Deficit Hyperactivity Disorder (ADHD)

Australia
Medical University of Vienna

Completed

Therapeutic Drug Monitoring in Child and Adolescent Psychiatry (TDMKJP)

Depression | Anorexia Nervosa | ADHD

Austria
Medical University of Graz
AIT Austrian Institute of Technology GmbH

Unknown

3-dimensional Sensor Technology to Quantify Leg-edema

ADHF

Austria
Shire

Completed

Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

Attention Deficit Hyperactivity Disorder (ADHD)

Spain, Germany, Ukraine, France, Italy, Austria, Belgium, Ireland, Netherlands, Poland, Romania, Sweden, United Kingdom
Sanofi

Completed

Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH Safety)

Hyponatremia | Inappropriate ADH Syndrome

United States, France, Brazil, Russian Federation, Australia, Germany, Switzerland, Belgium, Hungary, Hong Kong, Canada
Calcilytix Therapeutics, Inc., a BridgeBio company

Recruiting

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (CALIBRATE)

Autosomal Dominant Hypocalcemia (ADH)

United States, Australia, Denmark, Italy, France, Japan, Canada, Czechia, Netherlands

Clinical Trials on ADHD in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations